Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC

As stage IIIC non-small cell lung cancer (NSCLC) is not recommended for surgical resection, the survival and prognosis for stage IIIC NSCLC remain poor. More powerful and individualized therapies are urgently needed to improve the prognosis of stage IIIC NSCLC. Recently, immunotherapeutics have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yu, Duan, Weichen, Xu, Ran, Chen, Jiajia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655236/
https://www.ncbi.nlm.nih.gov/pubmed/38022567
http://dx.doi.org/10.3389/fimmu.2023.1268153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655236/
https://www.ncbi.nlm.nih.gov/pubmed/38022567
http://dx.doi.org/10.3389/fimmu.2023.1268153

Ejemplares similares